Vela purchased Great Basin for $1.4 million in June, and will reopen its Utah-based lab, rehire employees, and commercialize the firm's infectious disease platform.
Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.
Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.
True Health made its bid last week in an auction, increasing it from an original $32 million in order to beat out other potential buyers.
True Health will pay $37.1 million to acquire substantially all the assets of Health Diagnostic Laboratory, which is currently in Chapter 11 reorganization.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.
Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.
In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.